MRKMerck Sharp & Dohme LLCFinished
A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)
Hematological Malignancies
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 192 (final count)
- Started
- Sep 28, 2021
- Main results expected
- Dec 10, 2024
- Fully finished
- Dec 10, 2024
- Results posted
- Dec 17, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants With a Dose-Limiting Toxicity (DLT)
Measured over: Up to approximately 6 weeks
Percentage of Participants Who Experienced an Adverse Event (AE)
Measured over: Up to approximately 27 months
Percentage of Participants Who Discontinued Study Treatment Due to an AE
Measured over: Up to approximately 24 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05005442 · record last updated 2026-02-19 · checked 2026-11-09 15:47 UTC